E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens

Urology

Volumn 53, Issue 4, 1999, Pages 707-713

  De Marzo, Angelo M ^a   Knudsen, Beatrice ^a   Chan Tack, Kirk ^a   Epstein, Jonathan I ^a  

^a Department of Pathology ^*

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; UVOMORULIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; TROPHOBLAST; TUMOR CELL;

ADENOCARCINOMA; AGED; CADHERINS; DOWN-REGULATION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033119141     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00577-9     Document Type: Article

References (46)

1. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 20:1993;713-725.
2. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 24:1997;395-406.
3. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
4. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 20:1996;286-292.
5. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol. 159:1998;929-933.
6. Partin A.W., Steinberg G.D., Pitcock R.V., et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer. 70:1992;161-168.
7. Veltri R.W., Partin A.W., Epstein J.E., et al. Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl. 19:1994;249-258.
8. Veltri R.W., Miller M.C., Partin A.W., et al. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology. 48:1996;685-691.
9. Borre M., Hoyer M., Nerstrom B., et al. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate. 36:1998;244-249.
10. Silberman M.A., Partin A.W., Veltri R.W., et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:1996;772-779.
11. Gettman M.T., Bergstralh E.J., Blute M., et al. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate lack of significance for microvessel density analysis . Urology. 51:1998;79-85.
12. Sakr W.A., Grignon D.J. Prostate cancer indicators of aggressiveness . Eur Urol. 32:1997;15-23.
13. Gao X., Porter A.T., Grignon D.J., et al. Diagnostic and prognostic markers for human prostate cancer. Prostate. 31:1997;264-281.
14. Stattin P. Prognostic factors in prostate cancer. Scand J Urol Nephrol Suppl. 185:1997;1-46.
15. de la Taille A., Buttyan R., Benson M.C., et al. The role of tumor biomarkers as predictors of serum PSA recurrence after radical prostatectomy. Semin Urol Oncol. 16:1998;137-144.
16. Pettaway C.A. Prognostic markers in clinically localized prostate cancer. Tech Urol. 4:1998;35-42.
17. Gumbiner B.M. Cell adhesion the molecular basis of tissue architecture and morphogenesis . Cell. 84:1996;345-357.
18. Shiozaki H., Oka H., Inoue M., et al. E-cadherin mediated adhesion system in cancer cells. Cancer. 77:1996;1605-1613.
19. Ben-Ze'ev A. Cytoskeletal and adhesion proteins as tumor suppressors. Curr Opin Cell Biol. 9:1997;99-108.
20. He T.C., Sparks A.B., Rago C., et al. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512.
21. Umbas R., Schalken J.A., Aalders T.W., et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52:1992;5104-5109.
22. Bussemakers M.J., van Moorselaar R.J., Giroldi L.A., et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 52:1992;2916-2922.
23. Giroldi L.A., Schalken J.A. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer biological significance and clinical implications . Cancer Metastasis Rev. 12:1993;29-37.
24. Morton R.A., Ewing C.M., Nagafuchi A., et al. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res. 53:1993;3585-3590.
25. Otto T., Rembrink K., Goepel M., et al. E-cadherin a marker for differentiation and invasiveness in prostatic carcinoma . Urol Res. 21:1993;359-362.
26. Rembrink K., Otto T., Goepel M., et al. E-cadherin expression of the epithelial cell-cell-adhesion molecule in prostatic carcinoma and normal prostate . Investig Urol. 5:(Berl):1994;24-27.
27. Umbas R., Isaacs W.B., Bringuier P.P., et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54:1994;3929-3933.
28. Ross J.S., Figge H.L., Bui H.X., et al. E-cadherin expression in prostatic carcinoma biopsies correlation with tumor grade, DNA content, pathologic stage, and clinical outcome . Mod Pathol. 7:1994;835-841.
29. Cheng L., Nagabhushan M., Pretlow T.P., et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 148:1996;1375-1380.
30. Murant S.J., Handley J., Stower M., et al. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer. 33:1997;263-271.
31. Richmond P.J., Karayiannakis A.J., Nagafuchi A., et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer correlation with patient survival . Cancer Res. 57:1997;3189-3193.
32. Umbas R., Isaacs W.B., Bringuier P.P., et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer. 74:1997;374-377.
33. Kuczyk M., Serth J., Machtens S., et al. Expression of E-cadherin in primary prostate cancer correlation with clinical features . Br J Urol. 81:1998;406-412.
34. BIOMED-II Markers for Prostate Cancer Study Group , Ruijter E., van de Kaa C., Aalders T., et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer clinical implications . Mod Pathol. 11:1998;276-281.
35. Giroldi L.A., Bringuier P.P., Schalken J.A. Defective E-cadherin function in urological cancers clinical implications and molecular mechanisms . Invasion Metastasis. 14:1994;71-81.
36. Isaacs W.B. Molecular genetics of prostate cancer. Cancer Surv. 25:1995;357-379.
37. Cohen M.B., Griebling T.L., Ahaghotu C.A., et al. Cellular adhesion molecules in urologic malignancies. Am J Clin Pathol. 107:1997;56-63.
38. Schalken J.A. New perspectives in the treatment of prostate cancer. Eur Urol. 31:1997;20-23.
39. Biomed-II MPC Study Group , Ruijter E.T., Miller G.J., Aalders T.W., et al. Rapid microwave-stimulated fixation of entire prostatectomy specimens. J Pathol. 183:1997;369-375.
40. Suzuki H., Komiya A., Emi M., et al. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosom Cancer. 17:1996;225-233.
41. Carter B.S., Ewing C.M., Ward W.S., et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Nat Acad Sci USA. 87:1990;8751-8755.
42. Cher M.L., Bova G.S., Moore D.H., et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56:1996;3091-3102.
43. Latil A., Cussenot O., Fournier G., et al. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma identification of three independent regions . Cancer Res. 57:1997;1058-1062.
44. Graff J.R., Herman J.G., Lapidus R.G., et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:1995;5195-5199.
45. Novak A., Hsu S.C., Leung-Hagesteijn C., et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci USA. 95:1998;4374-4379.
46. Huttenlocher A., Lakonishok M., Kinder M., et al. Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J Cell Biol. 141:1998;515-526.